RxSight investors with losses over $75,000 may sue for damages.
ByAinvest
Sunday, Sep 21, 2025 7:25 am ET1min read
RXST--
The complaint alleges that RxSight and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose significant issues. These include adoption challenges and structural problems that led to declines in sales and utilization, overstated demand for the company's products, and an inability to meet previously issued financial guidance for fiscal year 2025 [1].
On July 8, 2025, after the market closed, RxSight reported significant declines in Light Adjustable Lens (LAL) sales, LAL utilization, and overall revenue. The company also lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint. The stock price subsequently fell by $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025 [1].
Investors are reminded that they have until September 22, 2025 to ask the Court to be appointed as lead plaintiff in the case. The lead plaintiff will oversee the litigation on behalf of the class, and any member of the class can choose to remain an absent class member [1].
Faruqi & Faruqi, LLP encourages anyone with information regarding RxSight's conduct to contact the firm, including whistleblowers, former employees, and shareholders. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995 [1].
For more information, investors can visit www.faruqilaw.com/RXST or contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) [1].
Faruqi & Faruqi, a securities law firm, is investigating potential claims against RxSight, Inc. for alleged misrepresentations in the company's financial statements between May 7, 2024 and July 8, 2025. The firm encourages investors who suffered losses exceeding $75,000 to contact Josh Wilson directly to discuss their options. A federal securities class action has been filed against the company, with a September 22, 2025 deadline to seek the role of lead plaintiff.
New York, Sept. 12, 2025 — Leading securities law firm Faruqi & Faruqi, LLP has announced that it is investigating potential claims against RxSight, Inc. (NASDAQ: RXST) for alleged misrepresentations in the company's financial statements between May 7, 2024 and July 8, 2025. The firm encourages investors who suffered losses exceeding $75,000 to contact Josh Wilson directly to discuss their options. A federal securities class action has been filed against the company, with a September 22, 2025 deadline to seek the role of lead plaintiff [1].The complaint alleges that RxSight and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose significant issues. These include adoption challenges and structural problems that led to declines in sales and utilization, overstated demand for the company's products, and an inability to meet previously issued financial guidance for fiscal year 2025 [1].
On July 8, 2025, after the market closed, RxSight reported significant declines in Light Adjustable Lens (LAL) sales, LAL utilization, and overall revenue. The company also lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint. The stock price subsequently fell by $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025 [1].
Investors are reminded that they have until September 22, 2025 to ask the Court to be appointed as lead plaintiff in the case. The lead plaintiff will oversee the litigation on behalf of the class, and any member of the class can choose to remain an absent class member [1].
Faruqi & Faruqi, LLP encourages anyone with information regarding RxSight's conduct to contact the firm, including whistleblowers, former employees, and shareholders. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995 [1].
For more information, investors can visit www.faruqilaw.com/RXST or contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet